Traders should await the full ePoster presentation at AAD 2026 for any meaningful clinical data. This release serves as a procedural update with no immediate financial implications. Monitor for subsequent analyst commentary following data disclosure.
Price Chart
Executive Summary
Aclaris Therapeutics announced the presentation of new results from the open-label Phase 2a trial of ATI-2138, an investigational oral covalent inhibitor of ITK and JAK3, in patients with moderate-to-severe atopic dermatitis. The data will be shared via an ePoster at the 2026 American Academy of Dermatology Annual Meeting. No clinical results, efficacy metrics, or safety data were disclosed in the press release.
Key Facts
- Aclaris Therapeutics is presenting new data from the Phase 2a trial of ATI-2138 at the 2026 AAD Annual Meeting.
- ATI-2138 is an oral covalent inhibitor of ITK and JAK3 being studied in moderate-to-severe atopic dermatitis.
- The results are being shared via an ePoster, which typically contains preliminary or supplemental data.
- No numerical results, efficacy endpoints (e.g., EASI reduction, IGA response), or safety findings were included in the release.
Financial Impact
No financial impact expected from this announcement alone — no data or commercial implications disclosed.
Risk Factors
- The lack of disclosed results limits the ability to assess the compound's potential.
- Phase 2a data in dermatology often show high variability; positive messaging does not guarantee clinical efficacy.
- Biotech stocks can be volatile around data readouts — absence of detail increases uncertainty.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3259830 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 10w ago | Institutional Cluster | $5.84 $6.44 | ▲ +10.27% | ▲ +10.72% | $3.81 (−34.85%) |
Aug 6, 2026 11w ago | 8-K | $6.09 $5.86 | ▼ −3.78% | ▼ −4.99% | $3.81 (−37.52%) |
Apr 28, 2026 25w ago | 8-K | $4.22 $4.75 | ▲ +12.56% | ▲ +10.87% | $3.81 (−9.83%) |
Apr 28, 2026 25w ago | Press Release | $4.22 $4.75 | ▲ +12.56% | ▲ +10.87% | $3.81 (−9.83%) |
Apr 23, 2026 26w ago | DEFA14A | $4.55 $4.47 | ▼ −1.76% | ▼ −3.24% | $3.81 (−16.37%) |
Mar 27, 2026 30w ago | Press Release | $3.52 $3.80 | ▲ +7.95% | ▲ +4.09% | $3.81 (+8.10%) |
Mar 20, 2026 31w ago | Press Release | $3.69 $3.52 | ▼ −4.61% | ▼ −2.46% | $3.81 (+3.12%) |
Mar 18, 2026 31w ago | Press Release | $3.66 $3.59 | ▼ −1.91% | ▼ −1.20% | $3.81 (+3.96%) |
Mar 11, 2026 32w ago | 8-K | $3.51 $3.74 | ▲ +6.55% | ▲ +7.53% | $3.81 (+8.40%) |
Feb 28, 2026 34w ago | Institutional Cluster | $3.05 $3.39 | ▲ +11.15% | ▲ +12.36% | $3.81 (+24.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers